Johnson & Johnson
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Johnson & Johnson reported 20 stock positions worth $427.3 million. Its top holding was Protagonist Therapeutics (PTGX) at 25.8% of the portfolio, followed by Rapport Therapeutics (RAPP, 12.0%) and Legend Biotech Corp.-ADR (LEGN, 9.3%). Compared with Q2 2024, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Clearside Biomedical and the biggest sale an exit from Aldeyra Therapeutics (ALDX).
- Most Recent 13F
- Q2 2026
- Location
- NEW BRUNSWICK, NJ
- CIK
- 0000200406
- Portfolio Value
- $427.3M (Q3 2024)
- SEC Filing
- 0000904454-24-000604 ↗ filed Nov 13, 2024
Holdings Value
Holdings 20 stocks · $427.3M
| PTGX Protagonist Therapeutics Inc. | 25.79% | 2,449,183 | $110.2M | No change |
| RAPP Rapport Therapeutics Inc. | 11.97% | 2,498,051 | $51.2M | No change |
| LEGN Legend Biotech Corp.-ADR | 9.29% | 814,586 | $39.7M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 8.86% | 1,979,173 | $37.9M | No change |
| CVRX CVRX Inc. | 8.46% | 4,103,430 | $36.2M | No change |
| NBTX Nanobiotix SA - ADR | 7.57% | 5,623,816 | $32.3M | No change |
| PRCT Procept Biorobotics Corp. | 6.71% | 357,939 | $28.7M | No change |
| MGTX Meiragtx Holdings PLC | 6.48% | 6,641,064 | $27.7M | No change |
| NMRA Neumora Therapeutics Inc. | 5.72% | 1,849,445 | $24.4M | No change |
| XNCR Xencor Inc. | 3.52% | 748,062 | $15.0M | No change |
| FATE Fate Therapeutics Inc. | 2.77% | 3,379,064 | $11.8M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.12% | 247,598 | $4.8M | No change |
| RLYB Rallybio Corp. | 1.00% | 3,636,363 | $4.3M | No change |
| NNOX Nano-X Imaging Ltd. | 0.23% | 158,852 | $966K | No change |
| VOR Vor Biopharma Inc. | 0.18% | 1,074,658 | $752K | No change |
| LAB Standard Biotools Inc. | 0.14% | 311,967 | $602K | No change |
| ACET Adicet Bio Inc. | 0.12% | 364,472 | $525K | No change |
| BIOMX INC | 0.05% | 192,321 | $196K | Reduce -90.0% |
| CLEARSIDE BIOMEDICAL INC | 0.02% | 82,481 | $105K | New |
| SENS Senseonics Holdings Inc. | 0.00% | 54,621 | $19K | No change |
Portfolio Sells Q2 2024 → Q3 2024
Portfolio Buys Q2 2024 → Q3 2024
| CLEARSIDE BIOMEDICAL INC | New | 0.02% | +0.02 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $798.7M | PTGX, NBTX, MGTX, RAPP, CTNM |
| Q1 2026 | 16 | $652.4M | PTGX, NBTX, MGTX, RAPP, CVRX |
| Q4 2025Amended | 17 | $555.0M | PTGX, NBTX, RAPP, MGTX, CVRX |
| Q3 2025Amended | 20 | $503.9M | PTGX, NBTX, MGTX, RAPP, CVRX |
| Q2 2025 | 20 | $334.1M | PTGX, MGTX, RAPP, LEGN, NBTX |
| Q1 2025 | 20 | $341.9M | PTGX, CVRX, MGTX, LEGN, RAPP |
| Q4 2024 | 20 | $386.1M | PTGX, CVRX, RAPP, MGTX, CTNM |
| Q3 2024 | 20 | $427.3M | PTGX, RAPP, LEGN, CTNM, CVRX |
| Q2 2024 | 20 | $400.7M | PTGX, RAPP, CVRX, LEGN, CTNM |
| Q1 2024 | 22 | $4.4B | KVUE, FUSN, CVRX, PTGX, SWAV |